Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis

Chengdu PLA General Hospital

Status

Unknown

Conditions

Rheumatoid Arthritis

Treatments

Drug: Qingkailing injection 40 ml

Drug: Puerarin injection 400 mg

Study type

Interventional

Funder types

Other

Identifiers

NCT02264301

QKL20140588

Details and patient eligibility

About

The purpose of this study is to evaluate the effect of Qingkailing injection versus Puerarin injection on withdrawal rate of corticosteroids in patients with active rheumatoid arthritis.

Enrollment

150 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

with active RA
without taking any other medication for the treatment of active RA in at least 4 last weeks
aged from 18 to 75 years
without conflict to the written, informed consent signed prior to the enrollment.

Exclusion criteria

being included in other clinical trial within the last 4 weeks
with abnormal liver or kidney function (more than 1 time above the high normal)
with serious cardiovascular disease
with hematologic disease
being in pregnancy, lactation period or under a pregnancy plan
with severe gastrointestinal disease
with contraindication or being allergic to the test drugs
being under the treatment of drugs within 1 previous week, that might affect the results of the trial, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, immunosuppressants, anti-ulcer drugs
being not compatible for the trial medication, or other circumstances at the discretion of investigators
without legal capacity or only with limited legal capacity.